Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.

Hu LL, Wang XX, Chen X, Chang J, Li C, Zhang Y, Yang J, Jiang W, Zhuang SM.

Carcinogenesis. 2007 Aug;28(8):1740-4. Epub 2007 May 10.

PMID:
17494054
2.

C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y.

Mol Cancer Ther. 2002 Jun;1(8):611-6.

3.

Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma.

Korenaga Y, Naito K, Okayama N, Hirata H, Suehiro Y, Hamanaka Y, Matsuyama H, Hinoda Y.

Int J Cancer. 2005 Nov 10;117(3):431-4.

4.

ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.

Fischer S, Lakatos PL; Hungarian IBD Study Group, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szilvasi A, Tulassay Z, Osztovits J, Papp J, Demeter P, Schwab R, Tordai A, Andrikovics H.

Scand J Gastroenterol. 2007 Jun;42(6):726-33.

PMID:
17505995
5.

ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.

Kim IS, Kim HG, Kim DC, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Lee GW.

Cancer Sci. 2008 Dec;99(12):2496-501. doi: 10.1111/j.1349-7006.2008.00985.x. Epub 2008 Nov 20.

6.

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, DeLoia JA.

Gynecol Oncol. 2012 Mar;124(3):575-81. doi: 10.1016/j.ygyno.2011.11.022. Epub 2011 Nov 21.

7.

Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis.

Cao HY, Zou P, Zhou H.

Gene. 2013 May 1;519(2):288-94. doi: 10.1016/j.gene.2013.01.066. Epub 2013 Feb 26.

PMID:
23485354
8.

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y.

Drug Metab Dispos. 2005 Jan;33(1):94-101. Epub 2004 Oct 8.

PMID:
15475413
9.

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.

Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles G.

Blood. 2004 May 1;103(9):3529-34. Epub 2003 Dec 30.

PMID:
14701701
10.

Association between the ABCG2 C421A polymorphism and Alzheimer's disease.

Fehér Á, Juhász A, László A, Pákáski M, Kálmán J, Janka Z.

Neurosci Lett. 2013 Aug 29;550:51-4. doi: 10.1016/j.neulet.2013.06.044. Epub 2013 Jul 1.

PMID:
23827224
11.

H2AFX polymorphisms are associated with decreased risk of diffuse large B cell lymphoma in Koreans.

Jin XM, Kim HN, Shin MH, Lee IK, Lee JS, Lee JH, Kim HJ, Choi JS, Juhng SW, Choi C.

DNA Cell Biol. 2011 Dec;30(12):1039-44. doi: 10.1089/dna.2010.1130. Epub 2011 Jun 1.

PMID:
21631283
12.

CD38 and interleukin 6 gene polymorphism in egyptians with diffuse large B-cell lymphoma (DLBCL).

Talaat RM, Abdel-Aziz AM, El-Maadawy EA, Abdel-Bary N.

Immunol Invest. 2015;44(3):265-78. doi: 10.3109/08820139.2014.989328. Epub 2015 Jan 7.

PMID:
25564959
13.

MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients.

Ni Y, Yin G, Xiao Z, Fan L, Wang L, Wu Y, Wu H, Qian S, Xu W, Li J, Miao K, Qiu H.

Tumour Biol. 2016 Jan;37(1):1237-44. doi: 10.1007/s13277-015-3930-0. Epub 2015 Aug 19.

PMID:
26286835
14.

Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.

Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y.

Cancer Lett. 2006 Mar 8;234(1):73-80. Epub 2005 Nov 21. Review.

PMID:
16303243
15.

Association of MNS16A VNTR and hTERT rs2736098: G>A polymorphisms with susceptibility to diffuse large B-cell lymphoma.

Essa ES, Alagizy HA.

Tumori. 2018 Jun;104(3):165-171. doi: 10.5301/tj.5000653. Epub 2018 May 8.

PMID:
28967095
16.

Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.

Østergaard M, Ernst A, Labouriau R, Dagiliené E, Krarup HB, Christensen M, Thorsgaard N, Jacobsen BA, Tage-Jensen U, Overvad K, Autrup H, Andersen V.

Scand J Gastroenterol. 2009;44(1):65-73. doi: 10.1080/00365520802400826.

PMID:
18819034
17.

Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.

Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, Ankathil R.

Biomed Pharmacother. 2014 Apr;68(3):343-9. doi: 10.1016/j.biopha.2014.01.009. Epub 2014 Feb 7.

PMID:
24581936
18.

The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.

Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Lou Y, Lee EJ.

Br J Clin Pharmacol. 2008 Aug;66(2):233-9. doi: 10.1111/j.1365-2125.2008.03184.x. Epub 2008 Apr 22.

19.

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.

Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB.

Pharmacogenet Genomics. 2008 May;18(5):439-48. doi: 10.1097/FPC.0b013e3282f974dc.

20.

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.

Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, Lou Y, Lee EJ.

J Pharm Sci. 2010 Feb;99(2):1046-62. doi: 10.1002/jps.21860.

PMID:
19569219

Supplemental Content

Support Center